Dignity Health | Comprehensive Blood and Cancer Center

Research site

(Unclaimed)

Location

6501 Truxtun, Avenue, Suite 900, Bakersfield, California, United States of America

Site insights

Top conditions

Top treatments

Paclitaxel

Bevacizumab

LY2835219

Gemcitabine

Abemaciclib

Erlotinib

Nivolumab

Dexamethasone

Bortezomib

Leucovorin

Parent organization

This site is a part of Dignity Health

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 85 total trials

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who c...

Enrolling

Multiple Myeloma

Drug: Ruxolitinib Oral Tablet [Jakafi]

Drug: Methylprednisolone

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered...

Enrolling

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

Drug: Gemcitabine

Drug: AMG 193

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER)

The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.

Active, not recruiting

Non Small Cell Lung Cancer

Drug: Erlotinib

Drug: Abemaciclib

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3)

The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women wit...

Active, not recruiting

Breast Cancer

Drug: Abemaciclib

Drug: Anastrozole

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2)

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Active, not recruiting

Advanced Breast Cancer

Drug: ARV-471

Drug: Fulvestrant

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered...

Enrolling

Non-small Cell Lung Cancer

Thoracic Tumors

Drug: Carboplatin

Drug: Pemetrexed

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol inv...

Active, not recruiting

Multiple Myeloma

Drug: Pomalidomide

Drug: Dexamethasone

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab...

Enrolling

Metastatic Non Small Cell Lung Cancer

Drug: Pembrolizumab

Drug: Carboplatin

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects (FLAMINGO-01)

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive an...

Enrolling

Breast Cancer

Biological: Placebo

Biological: GLSI-100

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent...

Enrolling

Solid Tumor

Melanoma Stage IV

Drug: GIM-531

Drug: Anti-PD-1 monoclonal antibody

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with u...

Active, not recruiting

Progressive Brain Metastasis

Unresectable or Metastatic Melanoma

Drug: Placebo in combination with nivolumab

Drug: HBI-8000 in combination with nivolumab

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (BRIA-ABC)

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[...

Enrolling

Breast Cancer

Breast Neoplasm

Drug: Cyclophosphamide

Drug: Interferon infiltration of the inoculation site